Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin

The Journal of Antimicrobial Chemotherapy
S HarlandT S Elliott

Abstract

The in-vitro activity of a new glycopeptide antibiotic, LY333328, was compared with vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, vancomycin and teicoplanin resistant enterococci, and vancomycin sensitive and resistant enterococci. MIC, MBC, and time-kill kinetics were determined for each agent. LY333328 displayed similar or improved MIC/MBC values in comparison with vancomycin and teicoplanin. Time-kill kinetics for LY333328 demonstrated significantly improved bactericidal activity against the isolates. These findings suggest that LY333328 has improved in-vitro activity over vancomycin and teicoplanin against a range of gram-positive organisms.

Citations

Nov 30, 2000·Current Infectious Disease Reports·M J Rybak, E A Coyle
Jul 20, 2004·Drugs·Murugan Raghavan, Peter K Linden
Oct 21, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert W FinbergMichael J Rybak
Jun 16, 2011·Scandinavian Journal of Infectious Diseases·Oguz Resat SipahiSercan Ulusoy
Aug 19, 2005·Expert Review of Anti-infective Therapy·Adolfo C Fernandez-ObregonCarolyn Willis
Jun 16, 2005·Expert Review of Anti-infective Therapy·Renee-Claude Mercier, Lenka Hrebickova
Mar 22, 2006·Expert Opinion on Investigational Drugs·Kristina E WardKerry L LaPlante
Jan 31, 2008·Expert Opinion on Investigational Drugs·Garyphallia Poulakou, Helen Giamarellou
Nov 2, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T Schulin, A Voss
May 18, 1999·Journal of Chemotherapy·E SillerströmC E Nord
Feb 4, 2003·Expert Opinion on Pharmacotherapy·Milind Khare, Deirbhile Keady
Feb 15, 2003·FEMS Microbiology Reviews·Norris E Allen, Thalia I Nicas
Apr 23, 2004·Drugs·Françoise Van BambekePaul M Tulkens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.